The interferon-inducible protein tetherin (also known as BST-2 or CD317) has emerged as a key component of the intrinsic immunity against retroviruses. Initially, tetherin was shown to restrict HIV-1 in the absence of the viral protein U (Vpu) by inhibiting the release of budding virions from infected cells. More recently, it has become clear that tetherin also acts as a pattern recognition receptor inducing NF-κB-dependent expression of antiviral and proinflammatory genes in HIV infected cells. Notably, tetherin does not only restrict retrovirus release but has activity against diverse enveloped viruses including Arena-, Filo- and Herpesvirues. Whereas the ability to restrict virion release is highly conserved among mammalian tetherin orthologs and probably an ancient function of this protein, innate sensing seems to be unique to the human and chimpanzee orthologs and thus an evolutionarily recent activity. The potent and broad antiviral activity of tetherin has driven the evolution of antagonists in many viruses. Simian (SIV) and human immunodeficiency viruses, for example, use at least three different proteins (Nef, Vpu or Env) to antagonize tetherin. The continuous arms race of tetherin with viral antagonists is probably also the reason for a unique deletion in the cytoplasmic tail of human tetherin that renders it resistant against SIV Nef. Since most SIVs – including the direct precursors of HIV-1 – use Nef to antagonize tetherin in their respective hosts, human tetherin poses a significant barrier to successful cross-species transmissions to humans. Interestingly, the four groups of HIV-1 (M, N , O and P) which arose from independent cross-species transmissions, have evolved different mechanisms to overcome this hurdle. Whereas pandemic HIV1 group M viruses switched from Nef to Vpu to counteract human tetherin, rare group P and N Vpus do not or only poorly antagonize this restriciton factor. In contrast, Nef proteins of epidemic HIV1 group O viruses target a region adjacent to the deletion in human tetherin to increase virion release from infected CD4+ T cells. Thus, potent tetherin counteraction may be a prerequisite for the efficient spread of lentiviruses in the human population. The coevolution of tetherin with primate lentiviruses, the molecular mechanisms underlying its antagonism and implications for spread and pathogenesis of human immunodeficiency viruses will be presented.